Effects of different doses of Remazolam on cardiac electrophysiology in patients undergoing surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082240

Enrollment

Unknown

Registered

2024-03-25

Start date

2024-04-01

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing surgery

Interventions

Group A1:Intravenous remazolam 0.2mg/kg

Group A2:Intravenous remazolam 0.3mg/kg

Group A3:Intravenous remazolam 0.4mg/kg

Group C:Intravenous saline

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 120 patients who underwent elective surgery, aged 20-50 years old, with ASA grades I-II and a body mass index of 18.5-23.9 kg/m2.

Exclusion criteria

Exclusion criteria: (1) Patients allergic to Remazolam; (2) Patients with respiratory dysfunction; (3) Patients with preoperative cardiopulmonary function, liver and kidney function, and electrolyte abnormalities; (4) Patients with obvious arrhythmia indicated by ECG, such as atrial arrhythmias, ventricular arrhythmias, and conduction block, or QTc interval = 450 ms for males and = 460 ms for females; (5) Take other drugs that affect ventricular repolarization, such as antiarrhythmic drugs, antibiotics, and antidepressants.

Design outcomes

Primary

Measure	Time frame
ECG;	—

Countries

China

Contacts

Public ContactYichen Ma

Guiyang Fourth People's Hospital

907161872@qq.com+86 139 8549 9547

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026